Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Wang FH, Zhang XT, Tang L, et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2024;44(1):127–72.

Article  CAS  PubMed  Google Scholar 

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.

Article  CAS  PubMed  Google Scholar 

Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015;21(24):7343–8.

Article  PubMed  PubMed Central  Google Scholar 

Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.

Article  CAS  PubMed  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–92.

Article  CAS  PubMed  Google Scholar 

Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.

Article  CAS  PubMed  Google Scholar 

Ikoma N, Hofstetter WL, Estrella JS, et al. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. 2018;117(8):1721–8.

Article  PubMed  PubMed Central  Google Scholar 

Ott K, Blank S, Becker K, et al. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398(2):239–49.

Article  PubMed  Google Scholar 

Neves FE, de Sant’Ana RO, Nunes LV, Pires AP, Da CM. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS. 2017;125(2):79–84.

Article  Google Scholar 

Schmidt T, Sicic L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014;110(7):1712–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sinnamon AJ, Savoldy M, Mehta R, et al. Tumor regression grade and overall survival following gastrectomy with preoperative therapy for gastric cancer. Ann Surg Oncol. 2023;30(6):3580–9.

Article  PubMed  Google Scholar 

Lai MY, Kang SY, Sun YT, et al. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. BMC Cancer. 2022;22(1):1031.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pei JP, Zhang CD, Fu X, et al. A novel TNM classification for colorectal cancers based on the metro-ticket paradigm. J Cancer. 2021;12(11):3299–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J, Zheng ZF, Wang W, et al. A novel TNM staging system for gastric cancer based on the metro-ticket paradigm: a comparative study with the AJCC-TNM staging system. Gastric Cancer. 2019;22(4):759–68.

Article  PubMed  Google Scholar 

Sasaki K, Morioka D, Conci S, et al. the tumor burden score: a new, “metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132–41.

Article  PubMed  Google Scholar 

Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43.

Article  PubMed  Google Scholar 

Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer-Am Cancer Soc. 2003;98(7):1521–30.

Google Scholar 

Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction data-driven staging for the seventh edition of the American joint committee on cancer/international union against cancer cancer staging manuals. Cancer-Am Cancer Soc. 2010;116(16):3763–73.

Google Scholar 

Harrell FJ, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.

Article  PubMed  Google Scholar 

Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17(2):228–43.

Article  PubMed  PubMed Central  Google Scholar 

Edeline J, Blanc JF, Johnson P, et al. A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver Int. 2016;36(12):1821–8.

Article  CAS  PubMed  Google Scholar 

Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.

Article  PubMed  Google Scholar 

van Smeden M, Moons K. Event rate net reclassification index and the integrated discrimination improvement for studying incremental value of risk markers. Stat Med. 2017;36(28):4495–7.

Article  PubMed  Google Scholar 

Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.

Article  CAS  PubMed  Google Scholar 

Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74.

Article  PubMed  PubMed Central  Google Scholar 

Sun Z, Zhu GL, Lu C, et al. A novel subclassification of pT2 gastric cancers according to the depth of muscularis propria invasion: superficial muscularis propria versus deep muscularis propria/subserosa. Ann Surg. 2009;249(5):768–75.

Article  PubMed  Google Scholar 

Lin JX, Yoon C, Desiderio J, et al. Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. Br J Surg. 2019;106(9):1187–96.

Article  CAS  PubMed  Google Scholar 

Li Z, Wang Y, Shan F, et al. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer. 2018;21(6):977–87.

Article  PubMed  Google Scholar 

Zhong Q, Chen QY, Parisi A, et al. Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: a multi-institutional study. Oncologist. 2021;26(1):e99–110.

Article  PubMed  Google Scholar 

Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934–9.

Article  PubMed  Google Scholar 

Xu X, Zheng G, Zhang T, Zhao Y, Zheng Z. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Cancer Chemother Pharmacol. 2019;84(3):635–46.

Article  PubMed  Google Scholar 

Lombardi PM, Mazzola M, Achilli P, et al. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: new perspectives from a single-center experience. J Surg Oncol. 2021;123(4):923–31.

Article  PubMed  Google Scholar